Bacterial meningitis: new treatment options to reduce the risk of brain damage

References

• van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37–62.
   PubMed Web of Science ®Google Scholar
• Ciofi Degli Atti M, Esposito S, Parola L, et al. GSAQ working group. In-hospital management of children with bacterial meningitis in Italy. Ital J Pediatr. 2014;40:87.
   PubMed Web of Science ®Google Scholar
• Oordt-Speets AM, Bolijn R, van Hoorn RC, et al. Global etiology of bacterial meningitis: a systematic review and meta-analysis. PLoS One. 2018;13:e0198772.
   PubMed Web of Science ®Google Scholar
• Azzari C, Moriondo M, Di Pietro P, et al. The burden of bacteremia and invasive diseases in children aged less than five years with fever in Italy. Ital J Pediatr. 2015;41:92.
   PubMed Web of Science ®Google Scholar
• Esposito S, Castellazzi L, Bosco A, et al. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention. Immunotherapy. 2014;6:395–408.
   PubMed Web of Science ®Google Scholar
• Martinelli D, Azzari C, Bonanni P, et al. Impact of Haemophilus influenzae type b conjugate vaccination on hospitalization for invasive disease in children fifteen years after its introduction in Italy. Vaccine. 2017;35:6297–6301.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:459–480.
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–1284.
   PubMed Web of Science ®Google Scholar
• van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. Clin Microbiol Infect. 2017;23:601–606.
   PubMed Web of Science ®Google Scholar
• Worls Health Organization (WHO). Meningococcal meningitis. Fact sheet. 2017 cited 2019 Jun 30 Available from: http://www.who.int/mediacentre/facsheets/fs141/en/
   Google Scholar
• Barichello T, Fagundes GD, Generoso JS, et al. Pathophysiology of neonatal acute bacterial meningitis. J Med Microbiol. 2013;62:1781–1789.
   PubMed Web of Science ®Google Scholar
• Gerber J, Nau R. Mechanisms of injury in bacterial meningitis. Curr Opin Neurol. 2010;23:312–318.
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Leib SL. Strategies to prevent neuronal damage in paediatric bacterial meningitis. Curr Opin Pediatr. 2006;18:112–118.
   PubMed Web of Science ®Google Scholar
• Deghmane AE, Alonso JM, Taha MK. Emerging drugs for acute bacterial meningitis. Expert Opin Emerg Drugs. 2009;14:381–393.
   PubMed Web of Science ®Google Scholar
• Tan YC, Gill AK, Kim KS. Treatment strategies for central nervous system infections: an update. Expert Opin Pharmacother. 2015;16:187–203.
   PubMed Web of Science ®Google Scholar
• Liechti FD, Grandgirard D, Leib SL. Bacterial meningitis: insights into pathogenesis and evaluation of new treatment options: a perspective from experimental studies. Future Microbiol. 2015;10:1195–1213.
   PubMed Web of Science ®Google Scholar
• Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;9:CD004405.
   Google Scholar
• Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993;14:436–441.
   PubMed Web of Science ®Google Scholar
• Trombetta AC, Meroni M, Cutolo M. Steroids and autoimmunity. Front Horm Res. 2017;48:121–132.
   PubMed Web of Science ®Google Scholar
• Leib SL, Heimgartner C, Bifrare YD, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res. 2003;54:353–357.
   PubMed Web of Science ®Google Scholar
• Irazuzta J, Pretzlaff RK, DeCourten-Myers G, et al. Dexamethasone decreases neurological sequelae and caspase activity. Intensive Care Med. 2005;31:146–150.
   PubMed Web of Science ®Google Scholar
• Gross HP, Verner JV Jr, Weller JM. Pneumococcal meningitis treated with hydrocortisone, ACTH, and antibiotics. Med Bull (Ann Arbor). 1956;22:329–331.
   PubMedGoogle Scholar
• Ribble JC, Braude AI. ACTH and adrenal steroids in the treatment of pneumococcal meningitisin adults. Am J Med. 1958;24:68–79.
   PubMed Web of Science ®Google Scholar
• Esposito S, Semino M, Picciolli I, et al. Should corticosteroids be used in bacterial meningitis in children? Eur J Paediatr Neurol. 2013;17:24–28.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N, Calabresi P, et al. An evolving redefinition of autoimmune encephalitis. Autoimmun Rev. 2019;18:155–163.
   PubMed Web of Science ®Google Scholar
• Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med. 1997;336:708–716.
   PubMed Web of Science ®Google Scholar
• McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta analysis of randomized clinical trials since 1988. JAMA. 1997;278:925–931.
   PubMed Web of Science ®Google Scholar
• de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549–1556.
   PubMed Web of Science ®Google Scholar
• Posadas E, Fisher J. Pediatric bacterial meningitis: an update on early identification and management. Pediatr Emerg Med Pract. 2018;15:1–20.
   PubMedGoogle Scholar
• Charlier C, Perrodeau É, Leclercq A, et al. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infect Dis. 2017;17:510–519.
   PubMed Web of Science ®Google Scholar
• Wehrli W, Staehelin M. Actions of the rifamycins. Bacteriol Rev. 1971;35:290–309.
   PubMedGoogle Scholar
• Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother. 2015;70:643–648.
   PubMed Web of Science ®Google Scholar
• Heidary M, Khosravi AD, Khoshnood S, et al. Daptomycin. J Antimicrob Chemother. 2018;73:1–11.
   PubMed Web of Science ®Google Scholar
• Mook-Kanamori B, Rouse M, Kang CI, et al. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect Dis. 2009;9:500.
   Web of Science ®Google Scholar
• Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother. 2006;57:720–723.
   PubMed Web of Science ®Google Scholar
• Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother. 2004;48:3928–3933.
   PubMed Web of Science ®Google Scholar
• Vivas M, Force E, Garrigos C, et al. Experimental study of the efficacy of daptomycin for the treatment of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother. 2014;69:3020–3026.
   PubMed Web of Science ®Google Scholar
• Vivas M, Force E, Tubau F, et al. Effect of dexamethasone on the efficacy of daptomycin in the therapy of experimental pneumococcal meningitis. Int J Antimicrob Agents. 2015;46:28–32.
   PubMed Web of Science ®Google Scholar
• Viladrich PF, Gudiol F, Linares J, et al. Evaluation ofvancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35:2467–2472.
   PubMed Web of Science ®Google Scholar
• Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenterobservational study. Clin Infect Dis. 2007;44:250–255.
   PubMed Web of Science ®Google Scholar
• Stucki A, Cottagnoud M, Winkelmann V, et al. Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H] choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob Agents Chemother. 2007;51:2249–2252.
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Schürch C, Cottagnoud P, et al. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 2007;51:2173–2178.
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Oberson K, Bühlmann A, et al. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 2010;54:1323–1326.
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Burri M, Agyeman P, et al. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob Agents Chemother. 2012;56:4289–4295.
   PubMed Web of Science ®Google Scholar
• Muri L, Grandgirard D, Buri M, et al. Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis. J Neuroinflamm. 2018;15:233.
   PubMed Web of Science ®Google Scholar
• Klein M, Höhne C, Angele B, et al. Adjuvant non-bacteriolytic and anti-inflammatory combination therapy in pneumococcal meningitis: an investigation in a mouse model. Clin Microbiol Infect. 2019;25:108.e9–108.e15.
   PubMed Web of Science ®Google Scholar
• Nauseef WM, Borregaard N. Neutrophils at work. Nat Immunol. 2014;15:602–611.
   PubMed Web of Science ®Google Scholar
• Brinkmann V. Neutrophil extracellular traps in the second decade. J Innate Immun. 2018;10:414–421.
   PubMed Web of Science ®Google Scholar
• Brandt CT, Lundgren JD, Lund SP, et al. Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect Immun. 2004;72:4647–4653.
   PubMed Web of Science ®Google Scholar
• Brandt CT, Lundgren JD, Frimodt-Møller N, et al. Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. J Neuroimmunol. 2005;166:126–131.
   PubMed Web of Science ®Google Scholar
• Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med. 2006;12:1056–1064.
   PubMed Web of Science ®Google Scholar
• Koedel U, Frankenberg T, Kirschnek S, et al. Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog. 2009;5:e1000461.
   PubMed Web of Science ®Google Scholar
• de Buhr N, Reuner F, Neumann A, et al. Neutrophil extracellular trap formation in the Streptococcus suis-infected cerebrospinal fluid compartment. Cell Microbiol. 2017;19. DOI:10.1111/cmi.12649.
   Web of Science ®Google Scholar
• Erni ST, Fernandes G, Buri M, et al. Anti-inflammatory and oto-protective effect of the small heat shock protein alpha B-crystallin (HspB5) in experimental pneumococcal meningitis. Front Neurol. 2019;10:570.
   PubMed Web of Science ®Google Scholar
• Mohanty T, Fisher J, Bakochi A, et al. Neutrophil extracellular traps in the central nervous system hinder bacterial clearance during pneumococcal meningitis. Nat Commun. 2019;10:1667.
   PubMed Web of Science ®Google Scholar
• Levin AB, Duff TA, Javid MJ. Treatment of increased intracranial pressure: a comparison of different hyperosmotic agents and the use of thiopental. Neurosurgery. 1979;5:570–575.
   PubMed Web of Science ®Google Scholar
• Menger JS, Charney JZ, Rivera VM, et al. Treatment with glycerol of cerebral oedema due to acute cerebral infarction. Lancet. 1971;2:993–997.
   PubMed Web of Science ®Google Scholar
• Gilsanz V, Rebollar JL, Buencuerpo J, et al. Controlled trial of glycerol versus dexamethasone in the treatment of cerebral oedema in acute cerebral infarction. Lancet. 1975;1:1049–1051.
   PubMed Web of Science ®Google Scholar
• McCurdy DK, Schneider B, Scheie HG. Oral glycerol: the mechanism of intraocular hypotension. Am J Ophthalmol. 1966;61:1244–1249.
   PubMed Web of Science ®Google Scholar
• Singhi S, Järvinen A, Peltola H. Increase in serum osmolality is possible mechanism for the beneficial effects of glycerol in childhood bacterial meningitis. Pediatr Infect Dis J. 2008;27:892–896.
   PubMed Web of Science ®Google Scholar
• Kilpi T, Peltola H, Jauhiainen T, et al. Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. The finnish study group. Pediatr Infect Dis J. 1995;14:270–278.
   PubMed Web of Science ®Google Scholar
• Peltola H, Roine I, Fernández J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2007;45:1277–1286.
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X, McCracken GH Jr. Glycerol and bacterial meningitis. Clin Infect Dis. 2007;45:1287–1289.
   PubMed Web of Science ®Google Scholar
• Blaser C, Klein M, Grandgirard D, et al. Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis. BMC Infect Dis. 2010;10:84.
   PubMed Web of Science ®Google Scholar
• Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis. 2011;11:293–300.
   PubMed Web of Science ®Google Scholar
• Sankar J, Singhi P, Bansal A, et al. Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian Pediatr. 2007;44:649‐656.
   Web of Science ®Google Scholar
• Molyneux EM, Kawaza K, Phiri A, et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatr Infect Dis J. 2014;33:214–216.
   PubMed Web of Science ®Google Scholar
• Roine I, Peltola H, Fernández J, et al. Influence of admission findings on death and neurological outcome from childhood bacterial meningitis. Clin Infect Dis. 2008;46:1248–1252.
   PubMed Web of Science ®Google Scholar
• Rottenberg DA, Hurwitz BJ, Posner JB. The effect of oral glycerol on intraventricular pressure in man. Neurology. 1977;27:600–608.
   PubMed Web of Science ®Google Scholar
• Vaziri S, Mansouri F, Sayad B, et al. Meta-analysis of studies comparing adjuvant dexamethasone to glycerol to improve clinical outcome of bacterial meningitis. J Res Med Sci. 2016;21:22.
   PubMed Web of Science ®Google Scholar
• Wall EC, Ajdukiewicz KM, Bergman H, et al. Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database Syst Rev. 2018;2:CD008806.
   PubMedGoogle Scholar
• Muri L, Leppert D, Grandgirard D, et al. MMPs and ADAMs in neurological infectious diseases and multiple sclerosis. Cell Mol Life Sci. 2019;76:3097–3116.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Estrada EY, Mobashery S. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents. Brain Res. 2007;1133:186–192.
   PubMed Web of Science ®Google Scholar
• Leib SL, Clements JM, Lindberg RLP, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor α converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001;124:1734–1742.
   PubMed Web of Science ®Google Scholar
• Leib SL, Leppert D, Clements J, et al. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 2000;68:615–620.
   PubMed Web of Science ®Google Scholar
• Meli D, Loeffler J, Baumann P, et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-α converting enzyme attenuates seizures and injury of the cerebral cortex. J Neuroimmunol. 2004;151:6–11.
   PubMed Web of Science ®Google Scholar
• Majeed S, Radotra BD, Sharma S. Adjunctive role of MMP-9 inhibition along with conventional anti-tubercular drugs against experimental tuberculous meningitis. Int J Exp Pathol. 2016;97:230–237.
   PubMed Web of Science ®Google Scholar
• Liechti FD, Grandgirard D, Leppert D, et al. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014;82:1710–1718.
   PubMed Web of Science ®Google Scholar
• Liechti FD, Bächtold F, Grandgirard D, et al. The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis. J Neuroinflamm. 2015;12:43.
   PubMed Web of Science ®Google Scholar
• Ricci S, Grandgirard D, Wenzel M, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis. 2014;14:726.
   PubMed Web of Science ®Google Scholar
• Paul R, Lorenzl S, Koedel U, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998;44:592–600.
   PubMed Web of Science ®Google Scholar
• Meli DN, Coimbra RS, Erhart DG, et al. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun. 2006;74:3890–3896.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Miller A, Lahat N, et al. Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. J Neurol Sci. 2003;206:43–48.
   PubMed Web of Science ®Google Scholar
• Yushchenko M, Weber F, Mäder M, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol. 2000;110:244–251.
   PubMed Web of Science ®Google Scholar
• Green JA, Thi Hong Chau T, Farrar JJ, et al. CNS infection, CSF matrix metalloproteinase concentrations, and clinical/laboratory features. Neurology. 2011;76:577–579.
   PubMed Web of Science ®Google Scholar
• Tsai H-C, Shi M-H, Lee SS-J, et al. Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with meningitis. Clin Microbiol Infect. 2011;17:780–784.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741–1751.
   PubMed Web of Science ®Google Scholar
• Green JA, Tran CT, Farrar JJ, et al. Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis. PLoS One. 2009;4:e7277.
   PubMed Web of Science ®Google Scholar
• Gerber J, Böttcher T, Hahn M, et al. Increased mortality and spatial memory deficits in TNF-α-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. Neurobiol Dis. 2004;16:133–138.
   PubMed Web of Science ®Google Scholar
• Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998;17:701–708.
   PubMed Web of Science ®Google Scholar
• Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005;72:85–87.
   PubMed Web of Science ®Google Scholar
• Pelkonen T, Roine I, Cruzeiro ML, et al. Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infect Dis. 2011;11:613–621.
   PubMed Web of Science ®Google Scholar
• Gianinazzi C, Grandgirard D, Imboden H, et al. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol. 2003;105:499–507.
   PubMed Web of Science ®Google Scholar
• Bifrare YD, Kummer J, Joss P, et al. Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis. J Infect Dis. 2005;191:40–45.
   PubMed Web of Science ®Google Scholar
• Mourvillier B, Tubach F, van de Beek D, et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA. 2013;310:2174–2183.
   PubMed Web of Science ®Google Scholar
• Pirracchio R, Journois D. Hypothermia for bacterial meningitis. JAMA. 2014;311:1357.
   PubMedGoogle Scholar
• Koelman DLH, Brouwer MC, van de Beek D. Targeting the complement system in bacterial meningitis. Brain. 2019 Aug 2:pii: awz222. DOI:10.1093/brain/awz222. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Rugemalira E, Roine I, Kuligowski J, et al. Protein oxidation biomarkers and myeloperoxidase activation in cerebrospinal fluid in childhood bacterial meningitis. Antioxidants (Basel). 2019;8:pii: E441.
   PubMedGoogle Scholar
• Barichello T, Generoso JS, Simões LR, et al. Role of oxidative stress in the pathophysiology of pneumococcal meningitis. Oxid Med Cell Longev. 2013;2013:371465.
   PubMed Web of Science ®Google Scholar
• Sheu JN, Liao WC, Wu UI, et al. Resveratrol suppresses calcium-mediated microglial activation and rescues hippocampal neurons of adult rats following acute bacterial meningitis. Comp Immunol Microbiol Infect Dis. 2013;36:137–148.
   PubMed Web of Science ®Google Scholar
• de Queiroz KB, Dos Santos Fontes Pereira T, Araújo MSS, et al. Resveratrol acts anti-inflammatory and neuroprotective in an infant rat model of pneumococcal meningitis by modulating the hippocampal miRNome. Mol Neurobiol. 2018;55:8869–8884.
   PubMed Web of Science ®Google Scholar